Live intraday price
Compare with our price levels
Close 2026-09-30: $9.99 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Price reached target T1 · 1 whale recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 5.2Moves ~$0.58 a day
⚖️ Positives and risks
- ●เซียนซื้อใหม่/ซื้อเพิ่มไตรมาสล่าสุด 1 ราย
- ●แนวโน้มระยะยาวเป็นขาขึ้น (เหนือ MA200 และ MA200 ชี้ขึ้น)
- ●แข็งแกร่งกว่าตลาด (S&P 500) +12% ใน 6 เดือน
- ●ราคาเป้าหมายนักวิเคราะห์เฉลี่ย 12.75 (upside +28%, 4 ราย)
- ●รายได้โต +94% เทียบปีก่อน
- ●ราคาแตะจุดขาย T1 แล้ว (แนวต้าน)
- ●ราคาห่างเหนือ MA200 ถึง +40% วิ่งมาไกลแล้ว
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
📊 Past earnings and price reaction
Actual EPS vs. analyst estimates · the price move on the first trading day after the report and over the next 20 trading days
Actual EPS -$0.22 · est. -$0.08 · Before open
Day 1
Next 20 days
Actual EPS -$0.08 · est. -$0.07 · Before open
Day 1
Next 20 days
Actual EPS -$0.06 · est. -$0.10 · Before open
Day 1
Next 20 days
Actual EPS -$0.07 · est. -$0.10 · After close
Day 1
Next 20 days
Actual EPS -$0.10 · est. -$0.10 · Before open
Day 1
Next 20 days
Actual EPS -$0.15 · est. -$0.14 · Before open
Day 1
Next 20 days
Actual EPS -$0.08 · est. -$0.13 · Before open
Day 1
Next 20 days
Actual EPS -$0.12 · est. -$0.18 · Before open
Day 1
Next 20 days
Listen to the earnings call or read the full report on IBRX's investor relations page ↗ · Earnings data from Yahoo Finance
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
Insider Monkey · 2026-09-30
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Stocktwits · 2026-09-30
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
Insider Monkey · 2026-09-23
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
Stocktwits · 2026-09-21
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
Zacks · 2026-09-18
🔬 Deep dive
For those who want the detailed numbers